<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study was undertaken to determine if the neuroprotective effect of <z:chebi fb="0" ids="16469">17beta-estradiol</z:chebi> (E(2)) when administrated after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is dose-dependent and if the therapeutic window for <z:chebi fb="0" ids="50114">estrogen</z:chebi> can be prolonged </plain></SENT>
<SENT sid="1" pm="."><plain>Ischemic injury was induced by permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (p-MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of E(2) at 30 min after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> resulted in a reduction in lesion volume </plain></SENT>
<SENT sid="3" pm="."><plain>A higher dose of E(2) extended the therapeutic window to 6h after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in 33% of the rats </plain></SENT>
<SENT sid="4" pm="."><plain>These findings suggest that postischemic treatment with <z:chebi fb="0" ids="50114">estrogen</z:chebi> affords protection against ischemic damage and that it acts within a clinically useful therapeutic window </plain></SENT>
</text></document>